Prevalence of HPV High-Risk Genotypes in Three Cohorts of Women in Ouagadougou (Burkina Faso)

Theodora M. Zohoncon1,3, Cyrille Bisseye1,4, Florencia W. Djigma1,2, Albert T. Yonli1, Tegwinde R. Compaore1,2, Tani Sagna1,2, Djeneba Ouermi1,2, Charlemagne M.R. Ouédraogo1,2, Simon A. Akpiona1 and Jacques Simpore1,2*

1"Pietro Annigoni" Centre for Bio-molecular Research CERBA / LABIOGENE, University of Ouagadougou, 01 BP 364 Ouagadougou 01, Burkina Faso
2 Saint-Camille Medical Center, 09 BP 444 Ouagadougou 09, Burkina Faso
3University of Parakou, PO Box 123, Republic of Benin
4Department of Biology, University of Science and Technique of Masuku (USTM); BP 943 Franceville, Gabon

Correspondence to: Prof. Jacques SIMPORE. "Pietro Annigoni" Centre for Bio-molecular Research CERBA / LABIOGENE, University of Ouagadougou, 01 BP 364 Ouagadougou 01, Burkina Faso. Burkina Faso, West Africa. E-mail: jacques.simpore@yahoo.fr

Competing interests: The authors have declared that no competing interests exist.

Published: September 2, 2013
Received: July 8, 2013
Accepted: August 20, 2013
Citation: Mediterr J Hematol Infect Dis 2013, 5(1): e2013059, DOI: 10.4084/MJHID.2013.059
This article is available from: http://www.mjhid.org/article/view/11958
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.
The development of cervical cancer is associated with high-risk Human papilloma viruses (HPV-HR). In sub-Saharan Africa cervical cancer is the most common cancer among women and the leading cause of death attributed to malignant tumors. This study aims to identify HPV genotypes within the 30'S and 50'S HPV families found in two previous studies from our laboratory, and to determine the prevalence of twelve HPV-HR genotypes in a population of women in Ouagadougou. The twelve HPV-HR genotypes were determined by real-time multiplex PCR, in 180 samples from the general population and among a group of HIV-1 infected women.
The most common genotypes found were HPV-35 (29.4%) and HPV-31 (26.1%) of the 30'S family, and HPV-52 (29.4%) and HPV-58 (20.6%) of the 50'S family. Multiple infections of HPV-HR were observed in 78.03% of infected women.
The frequencies of HPV genotypes from the 30'S and 50'S families were higher, while the genotypes HPV-16 and 18 were lower among the women in our study.

Introduction. Human papilloma viruses (HPV) are responsible for cervical cancer (CC), genital warts and verruca. They are the most common viruses in sexually transmitted infections. Their involvement in the development of cervical cancer is well established. In sub-Saharan Africa, CC is the most common cancer in women and the leading cause of mortality due to cancer. The global incidence of cervical cancer is 493,000 new cases each year, and 80% of women affected live in developing countries. CC and other
HPV related diseases are a real public health problem worldwide. Human immunodeficiency virus (HIV) and HPV co-infection is a risk factor for HPV’s infection persistence in Africa. In 2001, among women between the age of 15 and 49, HIV prevalence was of 3.5% in Ouagadougou (Burkina Faso). Among High Risk Human Papillomaviruses (HR-HPV), only types 16 and 18 are covered by the available HPV vaccines (Gardasil ® and Cervarix ®). Two previous studies from our laboratory carried out in Ouagadougou in 2011 by Djigma et al., and Ouedraogo et al. showed a high prevalence of HPV-HR from the 30'S (31, 33, 35, 39) and 50'S (51, 52, 56, 58, 59) families. However, the method of HPV genotyping (Use of polymerase chain reaction and hybridization assays) did not distinguish the different genotypes within 30'S and 50'S HPV families. The objective of this study was, firstly to determine the different genotypes within 30'S and 50'S HPV families detected in the two previous studies cited above and secondly to diagnose by real-time PCR, twelve HPV-HR genotypes in a cohort of women attending gynecological consultation in Ouagadougou.

Material and Methods

**Patients.** One hundred and eighty (180) women divided into three (3) groups were included in this study.

Cohort 1 consisted of 63 women of unknown HPV status, recruited from November 2012 to January 2013. Cohorts 2 and 3 were formed by 34 women positive for 30'S and 50'S HPV and 83 HIV-1-seropositive women positive for HPV-30'S and / or HPV50'S. Each woman completed a questionnaire to help determine her socio-economic, occupational and behavioral habits.

All women who could write signed a consent forms to participate to the study.

**Sample collection.** Samples were collected from the endocervical region with a sterile cotton swab. The collected samples were stored in transport medium (Sacace biotechnologies) and frozen at -20°C.

**Extraction of viral DNA and genotyping of HPV-HR.** DNA extraction was performed using the DNA-Sorb-A kit (Sacace Biotechnologies, Como, Italy) following the manufacturer's instructions. HPV-HR genotyping was performed by real time PCR using the HPV High Risk Typing Real-TM kit (Sacace Biotechnologies) in the SaCycler-96 Real Time PCR machine (Sacace Biotechnologies).

The HPV High Risk Typing Real-TM kit is based on two major processes: isolation of DNA from specimens, and multiplex Real Time amplification of 4 tubes for each sample. Each tube contains primers directed against regions of three HPV types and the ß-globin gene used as Internal Control.

**PCR conditions were as follows:** 1 cycle of 95°C for 15 minutes; 5 cycles of 95°C for 05s, 60°C for 20s and 72°C for 15s; and 40 cycles of 95°C for 05s, 60°C for 30s and 72°C for 15s.

**Statistical analysis.** Data were analyzed using SPSS 17.0 and Epi Info 3.5.1 softwares. The Chi-square test was used for comparisons. A difference was significant for p <0.05. The confidence interval (CI) and odd ratios (OR) were calculated with Epi Info 6.

**Results.**

**Socio-demographic characteristics of women.** The average age of women in cohorts 1 and 2 were respectively 33.2 ± 8.3 years (21 - 51) and 31.5 ± 10.3 years (19 - 60). Among the HIV-1 seropositive women, the mean age was 33.7 ± 6.2 years (20-53). The majority of the HPV-HR infected women was married and had a low level of education. Almost all of the women in the study had only one sexual partner. Table 1 shows the demographic characteristics of the women included in the study.

**Prevalence of HR-HPV genotypes.** Among all the 180 HPV-HR genotypes found, the most frequent were HPV-35 (29.4%) and HPV-52 (29.4%) followed by HPV-31 (26.1%), HPV-18 (25.0%), HPV-58 (20.6%), HPV-56 (18.9%), HPV-51 (14.4%), HPV-59 (13.9%), HPV-45 (12.8%) and HPV-33 (11.1%). The least frequent genotypes were HPV-16 (7.2%) and HPV-39 (6.7%). Among the HIV-1 seropositive women, the most represented genotype was HPV-35 with a prevalence of 49.4% while HPV-39 (9.6%) was the least common genotype. In women from cohort 1, 30.20% (19/63) were infected with at least one HPV-HR. HPV-52 (15.9%) was more prevalent while HPV-16 with a frequency of 1.6% was less frequent (Table 2). The cumulative prevalence of HPV-30'S and HPV-50'S was 43.0% in cohort 1 while the most common genotypes in cohort 2 was HPV-52 (35.3%) followed by HPV-58 (32.4%), HPV-35 (26.5%) and HPV-31 (20.6%). Table 3 shows the frequencies of the twelve HPV-HR genotypes among HIV positive women and women of unknown HIV status.

**Number of HPV-HR genotypes in infected women.** The number of HPV-HR genotypes in women ranged from 1 to 7 in HIV-1 seropositive women, and 1 to 5 in women from cohorts 1 and 2 (general population). The average number of genotype HPV-HR was significantly higher in HIV-1 positive women (3.5 ± 1.52) compared to women of the general population (2.1 ± 1.17) (p <0.001). In addition the majority of HIV-1 positive women (74.1%) had at least 3 HPV-HR genotypes, while the majority of women of the general population had only one genotype (74.1%).
Table 1. Socio-demographic, sexual and behavioral characteristics of women infected with high-risk HPV

| Age | Women of cohort 1 HPV positive n (%) | Women of cohort 2 HPV positive n (%) | HIV seropositive women HPV positive n (%) |
|-----|----------------------------------|----------------------------------|------------------------------------------|
| ≤ 30 years | 8 (42.1) | 21 (61.8) | 27 (32.5) |
| > 30 years | 11 (57.9) | 13 (38.2) | 56 (67.5) |

| Age at the time of the first sexual intercourse | Women of cohort 1 HPV positive n (%) | Women of cohort 2 HPV positive n (%) | HIV seropositive women HPV positive n (%) |
|-----------------------------------------------|----------------------------------|----------------------------------|------------------------------------------|
| < 20 years | 11 (57.9) | 25 (73.5) | 50 (60.2) |
| ≥ 20 years | 8 (42.1) | 9 (26.5) | 19 (22.9) |
| Not mentioned | - | - | 14 (16.9) |

| Use of preservatives | Women of cohort 1 HPV positive n (%) | Women of cohort 2 HPV positive n (%) | HIV seropositive women HPV positive n (%) |
|----------------------|----------------------------------|----------------------------------|------------------------------------------|
| yes | 3 (15.8) | 2 (5.9) | 31 (37.3) |
| no | 12 (63.2) | 19 (55.9) | 14 (16.9) |
| sometimes | 4 (21.0) | 8 (23.5) | 15 (18.1) |
| not specified | - | 5 (14.7) | 23 (27.7) |

| Oral Contraception | Women of cohort 1 HPV positive n (%) | Women of cohort 2 HPV positive n (%) | HIV seropositive women HPV positive n (%) |
|--------------------|----------------------------------|----------------------------------|------------------------------------------|
| yes | 1 (5.3) | 5 (14.7) | 61 (73.5) |
| no | 18 (94.7) | 29 (85.3) | 21 (25.3) |
| not specified | - | - | 1 (1.2) |

| Number of sexual partners | Women of cohort 1 HPV positive n (%) | Women of cohort 2 HPV positive n (%) | HIV seropositive women HPV positive n (%) |
|---------------------------|----------------------------------|----------------------------------|------------------------------------------|
| none | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 1 | 19 (100) | 28 (82.4) | 52 (62.7) |
| ≥ 2 | 0 (0.0) | 1 (2.9) | 0 (0.0) |
| not specified | - | 5 (14.7) | 31 (37.3) |

| Matrimonial Situation | Women of cohort 1 HPV positive n (%) | Women of cohort 2 HPV positive n (%) | HIV seropositive women HPV positive n (%) |
|-----------------------|----------------------------------|----------------------------------|------------------------------------------|
| single | 6 (31.6) | 9 (26.5) | 12 (14.5) |
| married | 11 (57.9) | 24 (70.6) | 43 (51.8) |
| widow | 2 (10.5) | 1 (2.9) | 18 (21.7) |
| divorced | - | - | 10 (12.0) |

| Level of education | Women of cohort 1 HPV positive n (%) | Women of cohort 2 HPV positive n (%) | HIV seropositive women HPV positive n (%) |
|--------------------|----------------------------------|----------------------------------|------------------------------------------|
| none | 10 (52.6) | 12 (35.3) | 28 (34.1) |
| primary | 4 (21.1) | 5 (14.7) | 29 (35.4) |
| secondary | 2 (10.5) | 10 (29.4) | 22 (26.9) |
| superior | 3 (15.8) | 7 (20.6) | 3 (3.7) |

| Tobacco Consumption | Women of cohort 1 HPV positive n (%) | Women of cohort 2 HPV positive n (%) | HIV seropositive women HPV positive n (%) |
|---------------------|----------------------------------|----------------------------------|------------------------------------------|
| yes | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| no | 19 (100) | 34 (100) | 83 (100) |

| HIV Status | Women of cohort 1 HPV positive n (%) | Women of cohort 2 HPV positive n (%) | HIV seropositive women HPV positive n (%) |
|------------|----------------------------------|----------------------------------|------------------------------------------|
| unknown | 7 (36.8) | - | 0 (0.0) |
| negative | 9 (47.4) | - | 0 (0.0) |
| positive | 3 (15.8) | - | 83 (100) |

Table 2. Prevalence of the twelve HPV-HR genotypes among the 63 women of unknown HPV status

| HPV Genotypes | Prevalence n (%) | Confidence Interval 95% |
|---------------|------------------|-------------------------|
| HPV-16 | 1 (1.6) | 0.1-9.7 |
| HPV-18 | 4 (6.3) | 2.1-16.3 |
| HPV-31 | 4 (6.3) | 2.1-16.3 |
| HPV-33 | 0 (0.0) | 0.0-7.2 |
| HPV-35 | 3 (4.8) | 1.2-14.2 |
| HPV-39 | 2 (3.2) | 0.6-12.0 |
| HPV-45 | 3 (4.8) | 1.2-14.2 |
| HPV-51 | 3 (4.8) | 1.2-14.2 |
| HPV-52 | 10 (15.9) | 8.3-27.7 |
| HPV-56 | 2 (3.2) | 0.6-12.0 |
| HPV-58 | 2 (3.2) | 0.6-12.0 |
| HPV-59 | 1 (1.6) | 0.1-9.7 |
| Total HPV-HR | 19 (30.2) | 19.6-43.2 |

population (66.7%) had no more than 2 HPV-HR genotypes (Table 4).

HPV-HR multiple infections were observed in 78.03% of the women of the study; but were 90.1% in HIV-1 infected women.

Discussion. This study first aim was to diagnose individually by real-time PCR genotypes HPV-HR 30’S and 50’S detected in two previous studies from our laboratory and the second aim was to genotype 12 HPV-HR in a cohort of women in Ouagaadougu. The prevalence of 30.2% of HPV-HR infection observed in this study (cohort 1) was comparable to that of 27.9% reported in Colombia. It was less than the prevalence of 72.6% reported in Burkina Faso, but more than the prevalence of 7.9% and 15.6% respectively reported in China and Nigeria. This could be explained by the fact that the majority of the women in our study had one sexual partner. Indeed, it
has been reported that having many sexual partners is associated with a high prevalence of HPV infection.12

In cohort 1 of this study (cohort 1) the cumulative prevalence of HPV-30’S and HPV-50’S families was 43.0%. We also found that the HPV-52 genotype was the most frequent both in our study population as well as in cohort 2 the (study by Ouedraogo et al, 2011). However, HPV-16 was the least common genotype observed in women. Our findings support those of Chen et al. who observed a high prevalence of HPV-52 (33.4%) and HPV-58 (15.93%) and a relatively low prevalence of HPV-16 (20.95%) and HPV-18 (8.36%) among women in China.13 HPV-HR genotypes (HPV-35, HPV-31, HPV-18 and HPV-33) infections prevalence was significantly higher among HIV-seropositive women than among women in the general population. HPV-35 was the most prevalent in seropositive women with a frequency of 49.4%. Our results are in agreement with previous studies which reported that the prevalence of HPV infection is higher among HIV-seropositive women.15-22 In Tanzania and South Africa Dols et al.23 reported that the most frequent HPV-HR in HIV positive women were HPV-52 (30%) and HPV-16 (26%) , there was no regional difference in the prevalence of HPV-18 and HPV-35.

Indeed, HIV increases the risk of developing cervical intra-epithelial neoplasia (CIN) and cervical cancer of the uterus.24 A recent study showed that the majority of HPV-HR genotypes found in this study among HIV-positive women had been detected in women with invasive cervical cancer, CIN2 and CIN3.25 We examined the carriage of HR-HPV genotypes among women of the three cohorts and found a significantly higher number of HPV-HR genotypes in HIV-positive women compared with those of the general population. Most HIV-positive women (74.1%) had at least 3 HPV-HR genotypes, while the majority of women in the general population

### Table 3. Frequency of the twelve HPV-HR genotypes among HIV+ women and women of HIV unknown status

| HPV Genotypes | Frequency n (%) | Confidence Interval 95% | Frequency n (%) | Confidence Interval 95% | Odds Risk (Confidence Interval 95%) | p values |
|---------------|-----------------|-------------------------|-----------------|-------------------------|-----------------------------------|----------|
| HPV-16        | 10 (12.0)       | 6.2-21.5                | 3 (5.7)         | 1.5-16.6                | 2.3 (0.5-11.1)                    | NS       |
| HPV-18        | 36 (43.4)       | 32.7-54.7               | 9 (17.0)        | 8.5-30.3                | 3.7 (1.5-9.5)                     | <0.01    |
| HPV-31        | 36 (43.4)       | 32.7-54.7               | 11 (20.8)       | 11.3-34.5               | 2.9 (1.2-7.0)                     | <0.01    |
| HPV-33        | 18 (21.7)       | 13.7-32.4               | 2 (3.8)         | 0.7-14.1                | 7.0 (1.5-46.3)                    | <0.01    |
| HPV-35        | 41 (49.4)       | 38.3-60.5               | 12 (22.6)       | 12.7-36.6               | 3.3 (1.5-7.8)                     | <0.01    |
| HPV-39        | 8 (9.6)         | 4.6-18.6                | 4 (7.5)         | 2.5-19.1                | 1.3 (0.3-5.5)                     | NS       |
| HPV-45        | 15 (18.1)       | 10.8-28.4               | 8 (15.1)        | 7.2-28.1                | 1.2 (0.5-3.5)                     | NS       |
| HPV-51        | 18 (21.7)       | 13.7-32.4               | 8 (15.1)        | 7.2-28.1                | 1.6 (0.6-4.3)                     | NS       |
| HPV-52        | 31 (37.3)       | 27.2-48.7               | 22 (41.5)       | 28.4-55.8               | 0.8 (0.4-1.8)                     | NS       |
| HPV-56        | 25 (30.1)       | 20.8-41.3               | 9 (17.8)        | 8.5-30.3                | 2.1 (0.8-5.4)                     | NS       |
| HPV-58        | 24 (28.9)       | 19.7-40.1               | 13 (24.5)       | 14.2-38.6               | 1.3 (0.5-3.0)                     | NS       |
| HPV-59        | 19 (22.9)       | 14.7-33.7               | 6 (11.3)        | 4.7-23.7                | 2.3 (0.8-7.1)                     | NS       |

### Table 4. Number of women infected by HPV genotypes

| Number of HPV genotypes identified per woman | Number of HIV-1 positive women | Number of women in cohort 1 and 2 |
|---------------------------------------------|--------------------------------|----------------------------------|
| Absolute Number | (%) | Absolute Number | (%) |
|-----------------|-----|----------------|-----|
| 1               | 8   | 9.9            | 21  | 41.2 |
| 2               | 13  | 16             | 13  | 25.5 |
| 3               | 24  | 29.6           | 10  | 19.6 |
| 4               | 16  | 19.8           | 5   | 9.8  |
| 5               | 12  | 14.8           | 2   | 3.9  |
| 6               | 5   | 6.2            | 0   | 0.0  |
| 7               | 3   | 3.7            | 0   | 0.0  |
| Total           | 81  | 100           | 51  | 100  |
(66.7%) had a maximum of 2 HPV-HR genotypes. Our results corroborate those found in South Africa which reported that HIV-positive women had an average of 2.4 HPV types per sample while HIV-negative women had an average of 0.7 HPV genotypes.21 Multiple HPV-HR infection was observed in 78.03% of infected women. 90.1% of the HIV-1 infected women had several HPV-HR infections.

The major limitation of this report is the sample size which is not representative of the female population of Ouagadougou. However, this pilot study has an epidemiological and clinical importance because it shows the prevalence of HR-HPV genotypes in Burkina Faso is different from other regions of the world with a preponderance of HPV-35, HPV-52, HPV-31 and HPV-18 genotypes. This study can have a real impact on the choice of immunization policy of the country as the existing HPV vaccines only cover HPV-16, HPV-18, HPV-6 and HPV-11 genotypes. The development of HPV vaccines covering the of HPV genotypes 30'S and 50'S families should be considered to protect all women from getting infected with these viruses.

Conclusion. We showed in this study a predominance of genotypes HPV-35, HPV-52, HPV-31 and HPV-18, respectively in HIV-1 seropositive women and in those of the two cohorts studied from the general population. A low prevalence of HPV-16 genotypes was also found. A large-scale study is needed to determine the epidemiology of HPV in the population in Burkina Faso.

Acknowledgements. The authors wish to thank the Saint Camille Medical Center and CERBA / LABIOGENE in Ouagadougou, University of Ouagadougou, Burkina Faso. They express their deep gratitude to the Italian Episcopal Conference (CEI) and the UEMOA economic support.

References:

1. Chelimo C, Woudes TA, Cameron LD, Elwood JM. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect. 2013; 66(3): 207-17. http://dx.doi.org/10.1016/j.jinf.2012.10.024 PMID:23103285
2. Koutskey L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997; 102(5A): 3-8. http://dx.doi.org/10.1016/S0002-9343(97)00172-9
3. Urmatta MT, Concha X, Riquelme G, Padilla O. [Knowlege and preventive behaviors related to cervical cancer and human papilloma virus in a group of Chilean adolescents], Rev Chilena Infectol. 2012; 29(6): 600-6. http://dx.doi.org/10.4067/S0716-101820120000300003 PMID:23412027
4. Alain S, Hantz S, Denis F. Papillomavirus : les virus et la physiopathologie de l'infection. Médecine thérapeutique/Pédiatrie. 2010; 13(1): 5-19.
5. Anorlu RI. What is the significance of the HPV epidemic? Can J Urol. 2008; 15(1): 3860-5. PMID:18304395
6. Ly A, Le camou du cot uterin : nouveaux vaccins, nouvelles perspectives ? J Afr Cancer. 2009; 1(65-67).
7. Hessel L. Introduction of vaccination against human papillomavirus in developing countries: update and perspectives. Med Trop. 2009; 69(4): 323-6. 
8. Paavenen J. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis. 2007; 11 Suppl 2(S3-9). http://dx.doi.org/10.1016/S1201-9712(07)60015-0
9. ONUSIDA. Rapport d'activités sur la riposte au SIDA du Burkina Faso (GARP 2012). 2012: 74p. Chen Q, Xie LX, Qing ZR, Li LJ, Luo ZY, Lin M, Zhang SM, Chen WZ, Lin BZ, Lin QL, Li H, Chen WP, Zheng PY, Mao LZ, Chen CY, Yang C, Zhan YZ, Liu XZ, Zheng JK, Yang LY. Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China. J Med Virol. 2013; 85(7): e32149. PMID:23284160 PMCid:PMC326448
10. Djigma FW, Owedraogo C, Karou DS, Sagna T, Bissaye C, Zeba M, Ouerni D, Goula C, Pietra V, Ghilat-Avod-Belem NW, Sanogo K, Sempore J, Pignatelli S, Ferri AM, Nikiema JB, Sempore J, Pignatelli S, Nikiema JB, Sempore J. [Epidemiology, characterization of genotypes of human papillomavirusin a population of women in Ouagadougou]. J Gynecol Obstet Biol Reprod (Paris). 2011; 40(7): 633-8. http://dx.doi.org/10.1016/j.jgyn.2011.05.012 PMID:21737213
12. Bedoya AM, Gaviria AM, Baena A, Borrero M, Duarte DF, Combata AL, Castano J, Grisales H, Sanchez GL. Age-specific seroprevalence of human papillomavirus 16, 18, 31, and 58 in women of a rural town of Colombia. Int J Gynecol Cancer. 2012; 22(2): 303-10. http://dx.doi.org/10.1097/JIGC.0b013e31873c2469 PMID:22228426
13. Chen Q, Xie LX, Qing ZR, Li LJ, Luo ZY, Lin M, Zhang SM, Chen WZ, Lin BZ, Lin QL, Li H, Chen WP, Zheng PY, Mao LZ, Chen CY, Yang C, Zhan YZ, Liu XZ, Zheng JK, Yang LY. Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China. PLoS One. 2012; 7(2): e32149. http://dx.doi.org/10.1371/journal.pone.0032149 PMID:22384160 PMCid:PMC326448
14. Pimentel VM, Jiang X, Mandavilli S, Umennyi Nwana C, Schnatz PF. Prevalence of high-risk cervical human papillomavirus and squamous intraepithelial lesion in Nigeria. J Low Genit Tract Dis. 2013; 17(2): 203-6. http://dx.doi.org/10.1097/LGT.0b013e3182612042 PMID:23343701
15. Baay MF, Kjetland EF, Ndhlovu PD, Deschoolmeester V, Mulduza T, Gomo E, Friis H, Midzi N, Gwanzura L, Mason PR, Vermorken JB, Gundersen SG. Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution. J Med Virol. 2004; 73(3): 481-5. http://dx.doi.org/10.1002/jmv.20115 PMID:15170646
16. Tornesello ML, Duraturo ML, Giorgi Rossi P, Sansone M, Piccoli R, Buonaguro L, Buonaguro FM. Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. J Gen Virol. 2008; 89( Pt 6): 1380-9. http://dx.doi.org/10.1099/vir.0.83553-0 PMID:18474553
17. Moodley JR, Constant D, Hoffman M, Salimo A, Allan B, Rybicki E, Hitzeroth I, Williamson AL. Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study. BMC Cancer. 2009; 9(275). PMID:19664216 PMCid:PMC2739859
18. Averbach SH, Gravitt PE, Nowak RG, Celentano DD, Dunbar MS, Morrison CS, Grimes B, Padian NS. The association between genital warts and cervical cancer. J Infect. 2013; 66(3): 207-17. http://dx.doi.org/10.1016/j.jinf.2012.10.024 PMID:23103285
19. Sagna T, Djigma F, Zeba M, Bisseye C, Karou SD, Ouermi D, Pietra V, Gnoula C, Sanogo K, Nikiema JB, Simpore J. Human Papillomaviruses prevalence and genital co-infections in HIV-seropositive women in Ouagadougou (Burkina Faso). Pakistan Journal of Biological Sciences. 2010; 13(19): 951-955. http://dx.doi.org/10.3923/pjbs.2010.951.955  PMid:21313918

20. Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbonye AK, Wabwire FM. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer. 2011; 6(1): 11. http://dx.doi.org/10.1186/1750-9378-6-11 PMid:21749691  PMCid:PMC3163594

21. Araujo AC, Carvalho NO, Teixeira NC, Souza TT, Murta ED, Farza IM, Correa CM, Lima MI, Del Castillo DM, Melo VH. Incidence of cervical intraepithelial neoplasia in a cohort of HIV-infected women. Int J Gynaecol Obstet. 2012; 117(3): 211-6. http://dx.doi.org/10.1016/j.iogo.2011.12.024  PMid:22445392

22. Teixeira NCP, Araujo ACL, Correa CM, da Costa Lodi C T, Lima MIM, de Oliveira Carvalho NO. Prevalence and risk factors for cervical intraepithelial neoplasia among HIV-infected women. Braz J Infect Dis. 2012; 16(2): 1413-8670. http://dx.doi.org/10.1016/S1413-8670(12)70299-4

23. Dols JA, Reid G, Brown J M, Tempelman H, Bontekoe TR, Quint WG, Boon ME. HPV Type Distribution and Cervical Cytology among HIV-Positive Tanzanian and South African Women. ISRN Obstet Gynecol. 2012: 514146. PMid:22811925  PMCid:PMC3394385

24. Jamieson DJ, Duerr A, Burk R, Klein RS, Paramsothy P, Schuman P, Cu-Uvin S, Shah K. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol. 2002; 186(1): 21-7. http://dx.doi.org/10.1067/mob.2002.119776  PMid:11810079

25. Pista A, de Oliveira CF, Lopes C, Cunha MJ. Human Papillomavirus Type Distribution in Cervical Intraepithelial Neoplasia Grade 2/3 and Cervical Cancer in Portugal: A CLEOPATRE II Study. Int J Gynecol Cancer. 2013; 23(3): 500-6. http://dx.doi.org/10.1097/IGC.0b013e318280f26e  PMid:23392401

26. Adler D, de Bruyn G, Laher F, Gray G, Allan BR, Williamson AL. Human papillomavirus genotype distribution among human immunodeficiency virus (HIV)-infected and non-HIV-infected women in Soweto, South Africa. J Clin Microbiol. 2008; 46(12): 4109-10. http://dx.doi.org/10.1128/JCM.01667-08  PMid:18945842  PMCid:PMC2593278

http://dx.doi.org/10.1097/QAD.0b013e3283377973

http://dx.doi.org/10.3923/pjbs.2010.951.955

http://dx.doi.org/10.1186/1750-9378-6-11

http://dx.doi.org/10.1016/j.iogo.2011.12.024

http://dx.doi.org/10.1016/S1413-8670(12)70299-4

http://dx.doi.org/10.1097/IGC.0b013e318280f26e

http://dx.doi.org/10.1128/JCM.01667-08